TARA Earnings — Protara Therapeutics, Inc. Common Stock Post-ER Performance | BigEarnings
TARA — Protara Therapeutics, Inc. Common Stock
XNAS · Healthcare · Biotechnology
Price$4.75
Market Cap$267.5M
P/E—
52W Range$2.77 – $7.82
Next Earnings2026-08-10
About Protara Therapeutics, Inc. Common Stock
Protara Therapeutics Inc is a clinical-stage biopharmaceutical company focused on advancing its therapies for the treatment of cancer and rare diseases. Its drug development pipeline includes: TARA-002, an investigational cell therapy in development for the treatment of non-muscle invasive bladder cancer (NMIBC) and lymphatic malformations (LMs); and IV Choline Chloride, an investigational phospholipid substrate replacement therapy, for patients receiving parenteral support, or PS, which includes both nutrition and fluids.
